These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9164345)

  • 1. Drug interactions with zileuton.
    Lau R
    Lancet; 1997 May; 349(9063):1479-80. PubMed ID: 9164345
    [No Abstract]   [Full Text] [Related]  

  • 2. Zileuton for asthma.
    Med Lett Drugs Ther; 1997 Feb; 39(995):18-9. PubMed ID: 9057778
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of zileuton on theophylline pharmacokinetics.
    Granneman GR; Braeckman RA; Locke CS; Cavanaugh JH; Dubé LM; Awni WM
    Clin Pharmacokinet; 1995; 29 Suppl 2():77-83. PubMed ID: 8620674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
    Awni WM; Hussein Z; Granneman GR; Patterson KJ; Dubé LM; Cavanaugh JH
    Clin Pharmacokinet; 1995; 29 Suppl 2():67-76. PubMed ID: 8620673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of zileuton on antipyrine and indocyanine green disposition.
    St Peter JV; Braeckman RA; Granneman GR; Locke CS; Cavanaugh JH; Awni WM
    Clin Pharmacol Ther; 1995 Mar; 57(3):299-308. PubMed ID: 7697947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.
    Wenzel SE; Kamada AK
    Ann Pharmacother; 1996; 30(7-8):858-64. PubMed ID: 8826571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
    Awni WM; Cavanaugh JH; Leese P; Kasier J; Cao G; Locke CS; Dube LM
    Eur J Clin Pharmacol; 1997; 52(1):49-54. PubMed ID: 9143867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
    Machinist JM; Kukulka MJ; Bopp BA
    Clin Pharmacokinet; 1995; 29 Suppl 2():34-41. PubMed ID: 8620669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
    Berger W; De Chandt MT; Cairns CB
    Int J Clin Pract; 2007 Apr; 61(4):663-76. PubMed ID: 17394438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
    Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
    J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
    Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
    Dahlén B; Nizankowska E; Szczeklik A; Zetterström O; Bochenek G; Kumlin M; Mastalerz L; Pinis G; Swanson LJ; Boodhoo TI; Wright S; Dubé LM; Dahlén SE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1187-94. PubMed ID: 9563738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-to-drug interaction of warfarin and nonsteroidal anti-inflammatory agents.
    Page M
    Conn Med; 2009; 73(10):610. PubMed ID: 19947061
    [No Abstract]   [Full Text] [Related]  

  • 14. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
    Samara E; Cavanaugh JH; Mukherjee D; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():84-91. PubMed ID: 8620675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
    Drazen J
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S233-7; discussion S247-8. PubMed ID: 9647605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
    Fischer AR; McFadden CA; Frantz R; Awni WM; Cohn J; Drazen JM; Israel E
    Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1203-7. PubMed ID: 7551371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Lipoxygenase inhibitor zileuton inhibits Ca(2+)-responses induced by glutoxim and molixan in macrophages.
    Krutetskaya ZI; Milenina LS; Naumova AA; Antonov VG; Nozdrachev AD
    Dokl Biochem Biophys; 2016 Jul; 469(1):302-4. PubMed ID: 27599517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-lipoxygenase inhibitory activity of zileuton.
    Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
    J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
    Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
    Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA
    J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.